Idera Pharmaceuticals Announces Tilsotolimod Updates
14. Dezember 2021 16:32 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its...
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
08. November 2021 16:14 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
09. August 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
Idera Pharmaceuticals Announces Corporate Updates
18. Mai 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of...
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
29. April 2021 16:10 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
18. März 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
01. März 2021 16:35 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and...
Idera Pharmaceuticals to Present at Upcoming Conferences
11. Januar 2021 06:02 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a...
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
15. Dezember 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
17. November 2020 16:27 ET
|
Idera Pharmaceuticals, Inc.
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...